Last reviewed · How we verify
Pneumococcal Vaccine Polyvalent
At a glance
| Generic name | Pneumococcal Vaccine Polyvalent |
|---|---|
| Also known as | Pneumovax 23 |
| Sponsor | The Jackson Laboratory |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (PHASE2)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal Vaccine Polyvalent CI brief — competitive landscape report
- Pneumococcal Vaccine Polyvalent updates RSS · CI watch RSS
- The Jackson Laboratory portfolio CI